<DOC>
	<DOC>NCT01298310</DOC>
	<brief_summary>To characterize the phenotype in patients with Morton's neuroma and to explore the effect of local administration of Xylocaine (lidocaine)</brief_summary>
	<brief_title>A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)</brief_title>
	<detailed_description>A randomised, double-blind, placebo-controlled, three-way cross-over single center study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)</detailed_description>
	<mesh_term>Neuroma</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Patients with a clinical diagnosis of Morton's neuroma with symptoms of at least 3 months duration in one foot (affected foot) Visual analogue scale (VAS) painscore of = 40 mm in the painful foot at daily activities during the previous week (visit 1) Allergy to lidocaine Scars or other dermal conditions on the feet that may interfere with study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Morton's neuroma, QST measurements</keyword>
</DOC>